Table 2.
Univariate analysis aOR (95% CI) | p | Multivariate analysis aOR (95% CI) | p | |
---|---|---|---|---|
Age | 1.007 (0.998–1.016) | 0.131 | 1.002 (0.993–1.014) | 0.55 |
Sex male | 1.878 (1.381–2.590) | <0.001 | 1.701 (1.199–2.412) | 0.003 |
Obesity | 0.802 (0.530–1.215) | 0.299 | ||
Diabetes mellitus | 1.585 (1.128–2.227) | 0.008 | 1.462 (1.000–2.137) | 0.05 |
Chronic hypertension | 1.192 (0.865–1.642) | 0.284 | ||
Ischemic heart disease | 0.998 (0.536–1.859) | 0.996 | ||
Chronic pulmonary disease | 0.812 (0.346–1.907) | 0.632 | ||
Cirrhosis | 1.993 (1.089–3.646) | 0.025 | 1.598 (0.816–3.130) | 0.17 |
Solid organ malignancy | 1.659 (1.082–2.543) | 0.02 | 1.669 (1.052–2.647) | 0.03 |
Hematological malignancy | 2.621 (1.583–4.340) | <0.001 | 2.553 (1.472–4.426) | <0.001 |
Autoimmune disease | 0.564 (0.369–0.861) | 0.008 | 0.848 (0.529–1.357) | 0.49 |
Solid organ transplant | 0.812 (0.439–1.503) | 0.507 | ||
Hematopoietic stem cell transplant | 0.831 (0.106–6.531) | 0.86 | ||
Systemic immunosuppression | 1.184 (0.851–1.648) | 0.315 | ||
SARS-CoV-2 vaccine | 0.413 (0.250–0.682) | <0.001 | 0.463 (0.272–0.788) | 0.005 |
Antiviral treatment | <0.001 | <0.001 | ||
No treatment | Ref | Ref | ||
Nirmatrelvir/ritonavir | 0.073 (0.030–0.179) | 0.084 (0.034–0.207) | ||
Remdesivir | 0.303 (0.197–0.466) | 0.301 (0.194–0.468) |
aOR, adjusted odds ratio; CI, confidence interval.